During the last three years enzymatic and immunological assays have been used concomitantly in our laboratory for the characterization of leukaemic cells and their normal counterparts. This study has evolved partly from our long-term interest in DNA metabolism of haemopoietic cells' and has been initiated partly by the extensive characterization of membrane structures (cALL antigen and Ia-like antigens) on leukaemic cells and their normal equivalent cells in Dr MF Greaves' laboratory at the Imperial Cancer Research Fund.2 Both avenues were greatly facilitated by the fact that large numbers of leukaemic samples have been made available for diagnostic testing through the MRC UKALL trials organised by Dr HEM Kay. The aims of these studies have always been threefold: (1) accurate diagnosis;3-5 (2) elaboration of reagents and test systems for the study of normal cells from which the various forms of acute lymphoblastic leukaemia (ALL) originate; and (3) standardization of new avenues for leukaemia treatments 8 An important advance in concomitant enzymatic and immunological analysis had taken place when Dr FJ Bollum developed a specific antibody to nuclear terminal deoxynucleotidyl transferase (TdT).9 By combining the analysis of nuclear TdT and membrane markers in double colour immunofluorescence tests, the immunoenzymatic analysis of individual single cells has become feasible.'0 The method is both simple and important since these double marker assays prove useful in the efficient analysis of new specific 'monoclonal' antibodies (made by somatic cell hybridization in mice) on even minute haemopoietic bodies for potential therapeutic use.
In our short account of enzyme markers below, it was expedient to include the relevant membrane marker observations (Table) . In the second part of the study, some of these immunological aspects are further discussed in greater detail. In this review we concentrate on advances made in the last three years. There have been a number of recent major reviews in this field. 2 16 In the human thymus, the TdT+ cells are predominantly localised in the cortex, while the majority of medullary thymocytes (which express characteristics of peripheral T lymphocytes) are TdT-. No TdT+ cells can be detected in circulating blood and peripheral lymphoid organs, apart from the transitional appearance of a low proportion of TdT+ cells in young animals (eg, 1-4-week-old rats).'7 The TdT+ thymic cell develops in rat, chicken, and human in late fetal life before TdT+ bone marrow cells can be detected. In the mouse, it can also be shown that the TdT+ bone marrow cell arises independently of the thymus, for example, in athymic 'nude' animals. '8 In 30 
ADENOSINE DEAMINASE
The importance of this enzyme in lymphoid development has been recognised since the observation that congenital ADA deficiency was a cause of T-cell deficiency.31 ADA is concerned in the degradation and recycling of purines, converting deoxyadenosine and adenosine to deoxyinosine and inosine, respectively (Fig. 3) . Although the enzyme is present in most body cells, the highest concentration occurs in thymic cortical cells,32 and the concentration is higher in mature T than B cells. Thymocytes and T cells are more susceptible to deoxyadenosine toxicity because they have a lower ability to degrade deoxyadenosine triphosphate (dATP) than B cells or other tissues, the 5' nucleotidase level being particularly low while they have high levels of deoxynucleoside kinases.33-35 Taheri et al. 36 have shown that Thy-ALL cells, unlike other cells, are unable to compartmentalise dATP into a degradative pool. Accumulation of dATP is thought to inhibit ribonucleotide reductase in T cell precursors and thus switch off the supply of dTTP, dATP, and dCTP and so inhibit DNA synthesis. An alternative suggested mechanism of toxicity in ADA deficiency is the accumulation of S-adenosyl-homocysteine (SAH) due to inhibition of SAH hydrolase by adenosine with inhibition of Sadenosyl methionine (SAM) synthesis and thus reduced methylation of RNA, DNA, and proteins.37
Recent studies in patients treated with the ADA inhibitor, deoxycoformycin (dCF), show that the rise in dATP rather than inhibition of SAH hydrolase correlates with cell killing.38 ADA in leukaemia Initial studies showed raised levels in acute leukaemia, whether myeloblastic or lymphoblastic,39 40 and levels in CLL lower than in normal-peripheral blood.4142 More levels has been shown to be higher in ALL than in AML, the highest levels occurring in Thy-ALL blasts. 43 (Fig. 3) , converting inosine or deoxyinosine hypoxanthine and guanosine or deoxyguanosine to guanine. Congenital deficiency of PNP, either complete or partial, due to the presence of a mutant enzyme causes immune deficiency with lack of T-cells but normal B-cell function5 which has been ascribed to the accumulation of deoxyguanosine and dGTP in T-cell precursors. 51 Blatt et al.52 found PNP to be significantly reduced in eight cases of Thy-ALL (range 10-100U, median 38) compared with 14 cases of non-T, non-B ALL (range 50-140U, median 79) or compared with normal peripheral blood mononuclear cells (range 10-230U, median 83).
On the other hand, cytochemical staining has suggested that it is the T-cells in peripheral blood that are PNP positive and B-cells negative with decreased activity in B-CLL compared to normal peripheral blood.53 54 Immunological markers in leukaemia It has been emphasised above that many of the new immunological reagents (anti-TdT, anti-ALL, antiIa-like, anti-HuTLA, and anti-myeloid antisera) play complementary roles in the differential diagnosis of leukaemias. The diagnostic accuracy can therefore be increased when the reagents to membrane antigens are used in combination with each other or with an antiserum detecting nuclear TdT enzyme (see above and ref. 10 ). An even more recent development has been the standardization of new monoclonal antibodies (McAb-s). Many Once the techniques of T-cell removal are perfected the elimination of residual leukaemic blasts can also be attempted. The obvious candidates are patients with Thy-ALL (eg, using antibody OKT1 1), B lymphoma, and perhaps cALL in second remission. The removal of TdT+ putative lymphoid precursors together with the residual cALL blasts may not have serious consequences69 although it remains to be seen whether the surviving patients develop hypogammaglobulinaemia.
Conclusions
Chemotherapy alone dramatically improved survival in leukaemia. Remission induction is successful in most patients but many relapse. Additional therapy is required. This needs to be selective with no or only minimal additional myelotoxicity. A better understanding of the enzymatic and antigenic make-up of leukaemic cells may lead to selective treatment protocols. It is already clear that ADA inhibitors kill Thy-ALL blasts selectively, and it may be that during the course of marrow transplantation the antibodies used will remove T cells or residual Thy-ALL blasts specifically without damaging myeloid stem cells. These efforts should be used in combination with conventional therapy and with each other. Allogeneic bone marrow transplantation may already be the choice of therapy for AML, and the studies described here can only improve the prospect of patients with AML, ALL, and other leukaemias.
